Analysts at Goldman Sachs (GS) lifted their price target on shares of Exact Sciences Corporation (EXAS) to $32 from $25 in a report released on Thursday. The firm currently has a ‘Buy’ rating on the stock.
Exact Sciences Corporation shares have surged 132% over the past 52 weeks, while the S&P 500 has gained 11.23% in the same period.
Shares of Exact Sciences gained 4.77% to $27.25 in recent trading.
—
Investment analysts at Citigroup (C) initiated coverage on shares of PTC Therapeutics, Inc. (PTCT) in a note issued to investors on Thursday. The firm set a ‘Buy’ rating and a $81.00 price target on the stock.
PTC Therapeutics shares have spiked 192% over the past 52 weeks, while the S&P 500 has gained 11.23% in the same period.
Shares of PTC Therapeutics, Inc. gained 5.27% to $53.56 in recent trading.
—
Piper Jaffray’s Gene Munster names Amazon.com Inc. (AMZN) as his ‘Top Large Cap Pick’ for 2015. The analyst reiterated an ‘Overweight’ rating and price target of $400.
AMZN has a median Wall Street price target of $350.00 with a high target of $450.00.
In the past 52 weeks, shares of Seattle, Washington-based company have traded between a low of $284.00 and a high of $408.06 and are now at $296.20. Shares are down 22.90% year-over-year and 25.05% year-to-date.
—
Citigroup (C) analysts are out with a report this morning initiating coverage of Intel Corporation (INTC) with a ‘Neutral’ rating and $35 price target. Shares of Intel are trading up more than 1.50% to $36.82 in Thursday’s session.
—
Citigroup (C) adds Applied Materials, Inc. (AMAT) to ‘Focus List’ with $36.00, 12-month base case estimate.
Applied Materials shares were 1.74% higher to 24.87% in mid-day trading Thursday. The name is up 40.72% in the year to date, while the S&P 500 index has gained 11.23%.
—
Shares of Tetraphase Pharmaceuticals, Inc. (TTPH) are up 15% to $38.10 in mid-day trading, after the company had its price target raised to $40 from $26 at Cantor Fitzgerald. The firm currently has a ‘Buy’ rating on the stock. TTPH was also raised to $46 from $28 at Needham.
Tetraphase shares have surged 181% over the past 52 weeks, while the S&P 500 index has gained 11.23% in the same period.
—
OvaScience, Inc. (OVAS) price target has been raised from $23 to $56 by Leerink Partners analysts, according to a research note published on Thursday. Leerink analysts maintained their ‘Outperform’ rating on the company. The new price target represents a potential upside of 17% from the name’s current pps. OVAS was also upgraded to ‘Outperform’ from ‘Neutral’ at Wedbush.
In the past 52 weeks, shares of OvaScience have traded between a low of $5.51 and a high of $49.94 and are now up 34% at $46.74. Ticker has gianed 410% year-to-date, compared with a 11.23% gain in the S&P 500.
—
Oracle Corporation (ORCL) price target has been raised from $48 to $50 by Canaccord Genuity analysts, according to a research note published on Thursday.
ORCL gained 8% to $44.51 in mid-day trading today. Approximately 29 million shares have already changed hands, compared to the stock’s average daily volume of 15.5 million shares.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply